196 related articles for article (PubMed ID: 38775878)
1. Sex Differences in Transthyretin Cardiac Amyloidosis: Unraveling the Complexities in Epidemiology, Pathophysiology, Diagnosis, and Treatment.
Vilches S; Martínez-Avial M; Méndez I; Gómez González C; Espinosa MÁ
Curr Heart Fail Rep; 2024 May; ():. PubMed ID: 38775878
[TBL] [Abstract][Full Text] [Related]
2. Sex differences in transthyretin cardiac amyloidosis.
Aimo A; Panichella G; Garofalo M; Gasparini S; Arzilli C; Castiglione V; Vergaro G; Emdin M; Maffei S
Heart Fail Rev; 2024 Mar; 29(2):321-330. PubMed ID: 37566193
[TBL] [Abstract][Full Text] [Related]
3. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
4. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
5. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
Gonzalez-Lopez E; Escobar-Lopez L; Obici L; Saturi G; Bezard M; Saith SE; AbouEzzeddine OF; Mussinelli R; Gagliardi C; Kharoubi M; Griffin JM; Dispenzieri A; Vilches S; Perlini S; Longhi S; Oghina S; Rivas A; Grogan M; Maurer MS; Damy T; Palladini G; Rapezzi C; Garcia-Pavia P
JACC CardioOncol; 2022 Nov; 4(4):442-454. PubMed ID: 36444226
[TBL] [Abstract][Full Text] [Related]
7. Clinical clues for suspecting wild-type transthyretin cardiac amyloidosis in patients with monoclonal gammopathy of undetermined significance: a case report.
Haga T; Okumura T; Harada Y; Hiraiwa H; Morimoto R; Kaneko S; Kato N; Shinoda M; Murohara T
Egypt Heart J; 2024 Jun; 76(1):74. PubMed ID: 38856864
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
[TBL] [Abstract][Full Text] [Related]
9. [Neurological manifestations of ATTR amyloidosis].
Pernice HF; Hahn K
Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
[TBL] [Abstract][Full Text] [Related]
10. Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies.
Warner AL
Pharmacotherapy; 2021 Dec; 41(12):1081-1091. PubMed ID: 34669976
[TBL] [Abstract][Full Text] [Related]
11. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
Shah SJ; Fine N; Garcia-Pavia P; Klein AL; Fernandes F; Weissman NJ; Maurer MS; Boman K; Gundapaneni B; Sultan MB; Elliott P
JAMA Cardiol; 2024 Jan; 9(1):25-34. PubMed ID: 37966817
[TBL] [Abstract][Full Text] [Related]
12. Concomitant Transthyretin Amyloidosis and Severe Aortic Stenosis in Elderly Indian Population: A Pilot Study.
Singal AK; Bansal R; Singh A; Dorbala S; Sharma G; Gupta K; Saxena A; Bhargava B; Karthikeyan G; Ramakrishnan S; Bisoi AK; Hote MP; Rajashekar P; Chowdhury UK; Devagourou V; Patel C; Ray R; Arawa SK; Mishra S
JACC CardioOncol; 2021 Oct; 3(4):565-576. PubMed ID: 34746852
[TBL] [Abstract][Full Text] [Related]
13. ATTR Epidemiology, Genetics, and Prognostic Factors.
Obi CA; Mostertz WC; Griffin JM; Judge DP
Methodist Debakey Cardiovasc J; 2022; 18(2):17-26. PubMed ID: 35414855
[TBL] [Abstract][Full Text] [Related]
14. Tafamidis improves myocardial longitudinal strain in A97S transthyretin cardiac amyloidosis.
Wu YA; Yu AL; Cheng MF; Lin LC; Lee MJ; Chou CH; Shun CT; Hsueh HW; Juang JJ; Tseng PH; Lin SP; Su MY; Chao CC; Hsieh ST; Tsai CH; Lin YH
Ther Adv Chronic Dis; 2024; 15():20406223231222828. PubMed ID: 38223905
[TBL] [Abstract][Full Text] [Related]
15. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.
Castaño A; Narotsky DL; Hamid N; Khalique OK; Morgenstern R; DeLuca A; Rubin J; Chiuzan C; Nazif T; Vahl T; George I; Kodali S; Leon MB; Hahn R; Bokhari S; Maurer MS
Eur Heart J; 2017 Oct; 38(38):2879-2887. PubMed ID: 29019612
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy.
Devesa A; Camblor Blasco A; Pello Lázaro AM; Askari E; Lapeña G; Gómez Talavera S; Taibo Urquía M; Rodríguez Olleros C; Tuñón J; Ibáñez B; Aceña Á
ESC Heart Fail; 2021 Aug; 8(4):2856-2865. PubMed ID: 33963812
[TBL] [Abstract][Full Text] [Related]
17. Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study.
Tsai CH; Chao CC; Hsieh ST; Yu AL; Wu YA; Cheng MF; Lee MJ; Chou CH; Shun CT; Hsueh HW; Jyh-Ming Juang J; Tseng PH; Su MY; Lin YH
Orphanet J Rare Dis; 2023 Sep; 18(1):289. PubMed ID: 37705003
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin treatment and cardiovascular outcome in RBP4/TTR
Li Z; Lv F; Wen X; Guo C; Li L; Cai X; Lin C; Zhang M; Yang W; Ji L
ESC Heart Fail; 2024 Feb; 11(1):179-188. PubMed ID: 37877450
[TBL] [Abstract][Full Text] [Related]
19. Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies.
Milandri A; Farioli A; Gagliardi C; Longhi S; Salvi F; Curti S; Foffi S; Caponetti AG; Lorenzini M; Ferlini A; Rimessi P; Mattioli S; Violante FS; Rapezzi C
Eur J Heart Fail; 2020 Mar; 22(3):507-515. PubMed ID: 31975495
[TBL] [Abstract][Full Text] [Related]
20. Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Zumbo G; Knight DS; Kotecha T; Francis R; Hutt DF; Rezk T; Rosmini S; Quarta CC; Whelan CJ; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
J Am Coll Cardiol; 2017 Jul; 70(4):466-477. PubMed ID: 28728692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
